adeno-associated viral vector delivered glucocerebrosidase gene therapy (Pfizer)

N/A

Report date: 2025/01/26 18:50:01

Base Information

Drug Nameadeno-associated viral vector delivered glucocerebrosidase gene therapy (Pfizer)
Drug Alias Nameadeno-associated virus vector based gene therapy (Pfizer)AAV-GBA
ClassificationBiologics
Mechanisms of ActionGlucosylceramidase stimulants
TargetsGlucosylceramidase
Therapy Area/IndicationsGaucher's disease type I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsGaucher's disease type I
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A